Francine Del Ricci

ES Cell International Pte Ltd. develops human embroyonic stem cell technologies for research and commercial applications. It develops an array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. The company was founded by Ariff Bongso, Robert Klupacs, Martin F. Pera, Reubinoff Benjamin and Alan Osborne Trounson in 2000 and is headquartered in Singapore.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada.

QD Solar, Inc. develops photovoltaic cells using colloidal quantum dot technology in Canada. Its quantum dot technology combines silicon solar cells with infrared solar cells in a hybrid architecture to harvest more of the solar spectrum than silicon alone. The company was founded by Sjoerd Hoogland and Edward Hartley Sargent in 2014 and is headquartered in Toronto, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

EnCellX, Inc. is a biotechnology company that operates in the field of biotechnology. The private company is based in San-Diego, CA and has subsidiaries in Israel. The company was founded by Aditya P. Mohanty.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada.

Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.

Bedside Clinical Systems, Inc. develops Responses to Illness Severity Quantification (RISQ) framework severity of illness clinical decision support for frontline healthcare professionals, hospital administrators and quality managers. It provides BedsidePEWS, that uses the RISQ framework to empower frontline clinicians who care for hospitalized children. The company was founded by Christopher Parshuram in March 2011 and is headquartered in Toronto, Canada.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Hadasit Bio-Holdings Ltd. /Private Equity/ (Hadasit Bio-Holdings /Private Equity/) is a private equity division of Hadasit Bio-Holdings Ltd. founded in 2005. The firm is headquartered in Jerusalem, Israel.

LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.